RETRACTED: Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study.

Abstract

AIM:

We evaluated the effects of acarbose on insulin resistance parameters in diabetic patients before and after a standardized oral fat load (OFL).

MATERIALS AND METHODS:

Patients were assigned to take acarbose 50 mg three times a day or placebo; after the first month, acarbose was titrated to 100 mg three times a day. We evaluated body mass index, glycemic control, fasting plasma insulin (FPI), post-prandial plasma insulin (PPI), homeostasis model assessment insulin resistance index (HOMA-IR), blood pressure, lipid profile, retinol binding protein-4 (RBP-4), adiponectin (ADN), tumor necrosis factor-α and resistin (r). Furthermore, at the baseline and at the end of the study, all patients underwent an OFL and an euglycemic hyperinsulinemic clamp.

RESULTS:

We observed that acarbose was better than placebo in improving glycemic control and HOMA-IR and that it was also more effective in improving lipid profile, RBP-4 and ADN. Regarding FPI, PPI and r, we did not obtain any significant differences between the two groups. During the second OFL, performed after 7 months of therapy with acarbose, we observed a significant decrease of blood glucose, lipid profile and all insulin resistance parameters peaks compared with the OFL administered at baseline with acarbose, but not with placebo.

CONCLUSION:

Acarbose was more effective than placebo in improving glycemic and lipid profile and in reducing the post-OFL peaks of the various parameters including the insulin resistance biomarkers.

• Authors: Giuseppe Derosa, Pamela Maffioli, Angela D'Angelo, Elena Fogari, Lucio Bianchi, Arrigo F G Cicero
• Journal: Journal of diabetes and its complications (J Diabetes Complications) 2011 Jul-Aug Vol. 25 Issue 4 Pg. 258-66 ISSN: 1873-460X [Electronic] United States
• PMID: 21367625 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Retracted Publication)
• Copyright: Copyright © 2011 Elsevier Inc. All rights reserved.

Chemical References

• ADIPOQ protein, human
• Adiponectin
• Biomarkers
• Blood Glucose
• Dietary Fats
• Glycated Hemoglobin A
• Hypoglycemic Agents
• Lipids
• RBP4 protein, human
• Retinol-Binding Proteins, Plasma
• hemoglobin A1c protein, human
• Acarbose

Topics

• Acarbose (adverse effects, therapeutic use)
• Adiponectin (blood)
• Biomarkers (blood)
• Blood Glucose (analysis)
• Diabetes Mellitus, Type 2 (blood, drug therapy, metabolism)
• Dietary Fats (metabolism)
• Double-Blind Method
• Female
• Glucose Clamp Technique
• Glycated Hemoglobin (analysis)
• Humans
• Hyperglycemia (prevention & control)
• Hypoglycemic Agents (adverse effects, therapeutic use)
• Insulin Resistance
• Intention to Treat Analysis
• Lipids (blood)
• Male
• Middle Aged
• Patient Dropouts
• Retinol-Binding Proteins, Plasma (analysis)